摘要
目的探讨非小细胞肺癌(non-small-cell lung cancer,NSCLC)组织中RET融合基因与胸苷酸合成酶(thymidylate synthase,TYMS)基因mRNA的表达及其相关性。方法应用实时荧光定量PCR方法检测642例NSCLC组织中RET基因及TYMS基因mRNA的表达,分析二者表达与临床病理特征的关系及二者的相关性。结果NSCLC组织中RET融合基因阳性率占0.93%(6/642);TYMS基因mRNA高表达占63.55%(408/642)。二者表达与患者的性别、年龄、吸烟情况、肿瘤大小、淋巴结是否转移及临床分期等临床病理特征无关(P>0.05)。RET融合基因mRNA表达与TYMS基因mRNA表达显著相关(P<0.05)。结论非小细胞肺癌RET融合基因阳性患者TYMS基因倾向低表达,或许能从一线化疗药培美曲塞中受益。
Objective To investigate mRNA expressions and relationship of RET fusion and thymidylate syn- thase （TYMS） genes in non-small-cell lung cancer （NSCLC） tissues. Methods The mRNA expressions of RET fusion and of TYMS genes in NSCLC tissues of 642 patients were detected using real-time fluorescent quantitative PCR method, and the relationship and its correlation between the expression and clinicopathological features were also analyzed. Results The positive rate of RET fusion gene in NSCLC was 0.93% （6/642） ; high mRNA expression of TYMS gene was 63.55% （408/642）. The expressions showed no relationship with gender, age, smoking, tumor size, lymph node metastasis and clinical stages （P 〉 0. 05）. The mRNA expressions between RET fusion and TYMS genes showed positive correlation （P 〈 0. 05）. Conclusion Thymidylate synthase gene shows low expression level in NSCLC patients with pos- itive RET fusion gene, which may benefit from Pemetrexed of first-line chemotherapy drug.
出处
《解放军医药杂志》
CAS
2015年第11期52-55,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
吴阶平医学基金会临床科研专项资助基金项目(320.6750.1360)
浙江省医学科学研究基金项目(2013KBY051)
浙江省中医药管理局科研基金(2013ZQ005)
山西省科技攻关基金(20130313021-16)
关键词
癌
非小细胞肺
RET融合基因
胸苷酸合成酶
病理学
分子
基因表达调控
肿瘤
Carcinoma, non-small-cell lung
RETfusion gene
Thymidylate synthetase
Pathology, molecular
Gene expression regulation, neoplastic
